The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular ...

About one-third of U.S. adults without diabetes who are eligible for weight loss treatment with glucagon-like peptide 1 ...

According to research published in JAMA Network Open, the use of anti-obesity medications, including glucagon-like peptide-1 ...

USA: A recent study, published in JAMA Network Open as a research letter, highlights a significant link between anti-obesity ...

It's four o'clock in the morning and I've been walking in a tight circle in my bedroom, on-and-off, for three hours.

While B-ALL is the most common childhood cancer and one of the most treatable, some patients face grim outcomes after they ...

Recently published “gold-standard” studies of antidepressant withdrawal flag misdiagnosis, confounding, and rushed tapering ...

Skeletal Muscle Health Amid Growing Use of Weight Loss Medication. A recent commentary published in The Lancet journal highlights the critical importance of skeletal ...

New Jerseyans are worried about the cost of services, unexpected medical bills, monthly premiums and prescription drug costs, ...

thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut ...

Rybelsus in combination with standard T2DM therapy reduced the risk of major cardiovascular events by 14% in patients with ...

Semaglutide and liraglutide are associated with a reduced risk for hospitalization due to alcohol use disorder (AUD).